A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Filanesib (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms AfFIRM
- Sponsors Array BioPharma
- 12 Dec 2016 Status changed from completed to active, no longer recruiting.
- 26 Jul 2016 Status changed from active, no longer recruiting to completed.
- 27 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Jul 2016.